Talaris Therapeutics, Inc.
Talaris Therapeutics, Inc. (TALS) Stock Overview
Explore Talaris Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
116.4M
P/E Ratio
-0.74
EPS (TTM)
$-1.74
ROE
-0.33%
TALS Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Talaris Therapeutics, Inc. (TALS) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $0.77.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.74 and a market capitalization of 116.4M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.